Abstract P3-11-05: Predictive gene signatures of adjuvant capecitabine benefit in triple negative breast cancer in the FinXX trialSaranya Chumsri, E. Aubrey Thompson, LS Lauttia et al.|Cancer Research|2019Cited by 1
Abstract PD5-06: Prognostic value of molecular tumor infiltrating lymphocyte (mTIL) signatures in HER2-positive breast cancer patients in N9831 and FinHer/FinXX trialsSaranya Chumsri, E. Aubrey Thompson, DJ Serie et al.|Cancer Research|2017Cited by 0